Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 106 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Canakinumab adjuvant therapy for treating completely resected non-small-cell lung cancer	Canakinumab (Ilaris; ACZ885)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2022	View \| Download
Canakinumab in addition to pembrolizumab and platinum-based chemotherapy for locally advanced or metastatic non-small-cell lung cancer (NSCLC)	Canakinumab (Ilaris; ACZ885) , Pembrolizumab (Keytruda; MK-3475)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2021	View \| Download
Capmatinib for advanced non-small cell lung cancer	Capmatinib (INC280)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2021	View \| Download
Cemiplimab as a monotherapy for advanced or metastatic non-small-cell lung cancer whose tumours express PD-L1 – first line	Cemiplimab (Libtayo; REGN2810)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2020	View \| Download
Cemiplimab in combination with chemotherapy for advanced or metastatic non-small cell lung cancer – first-line	Cemiplimab (Libtayo; REGN2810) , Ipilimumab (Yervoy; BMS 734016; MDX 101)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2021	View \| Download
Cobolimab with dostarlimab and docetaxel for advanced non-small-cell lung cancer after anti-PD-L1 therapy and chemotherapy	Cobolimab , Docetaxel (Taxotere; docetaxel trihydrate; docetaxel anhydrous) , Dostarlimab (TSR-042; Jemperli)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2023	View \| Download
Crizotinib (Xalcori) for locally advanced or metastatic Non‐Small Cell Lung Cancer (NSCLC)	Crizotinib (Xalkori; PF-02341066; Xalkor)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2018	View \| Download
Datopotamab deruxtecan for previously treated advanced non-small-cell lung cancer	Datopotamab deruxtecan (DS-1062)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2023	View \| Download
Durvalumab (Imfinzi) monotherapy for advanced or metastatic non-small cell lung cancer (EGFR and ALK wild type) – first line	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2017	View \| Download
Durvalumab for advanced, EGFR/ALK wild-type, high PD-L1 expression, non-small cell lung cancer- first line	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2020	View \| Download